Keros Therapeutics (NASDAQ:KROS) Trading Up 7% – Time to Buy?

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) traded up 7% during mid-day trading on Tuesday . The company traded as high as $61.02 and last traded at $60.70. 120,312 shares were traded during mid-day trading, a decline of 68% from the average session volume of 372,710 shares. The stock had previously closed at $56.73.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on KROS shares. Scotiabank initiated coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target for the company. Jefferies Financial Group began coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Bank of America cut their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Finally, Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Price Performance

The company has a market cap of $2.52 billion, a price-to-earnings ratio of -11.67 and a beta of 1.20. The firm’s 50-day moving average price is $59.49 and its 200-day moving average price is $52.28.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same period last year, the business earned ($1.33) EPS. The business’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its position in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC increased its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the period. Vanguard Group Inc. raised its position in shares of Keros Therapeutics by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after acquiring an additional 113,563 shares during the last quarter. Darwin Global Management Ltd. grew its holdings in shares of Keros Therapeutics by 6.3% in the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after buying an additional 89,952 shares during the period. Finally, Point72 Asset Management L.P. increased its position in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.